{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:33:33Z","timestamp":1792197213511,"version":"4.4.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.rmr.2023.10.010","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T08:30:44Z","timestamp":1701073844000},"page":"29-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analyse pharmacologique du traitement des pneumopathies \u00e0 Mycobacterium abscessus"],"prefix":"10.1016","volume":"41","author":[{"given":"L.","family":"Kassegne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Veziris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fraisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2023.10.010_bib0765","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/jid.1953.18","article-title":"An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region: report of a case with a study of the organism, Mycobacterium abscessus, n. sp.1","volume":"20","author":"Moore","year":"1953","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.rmr.2023.10.010_bib0770","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/ajrccm.154.2.8756832","article-title":"Nontuberculous mycobacteria in cystic fibrosis. An autopsy study","volume":"154","author":"Tomashefski","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib0775","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1471-2180-8-184","article-title":"Biofilm development by potentially pathogenic non-pigmented rapidly growing mycobacteria","volume":"8","author":"Esteban","year":"2008","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib0780","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1183\/13993003.01102-2015","article-title":"Chronic pulmonary disease with Mycobacterium abscessus complex is a biofilm infection","volume":"46","author":"Qvist","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2023.10.010_bib0785","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1164\/rccm.201508-1586IM","article-title":"Biofilm formation by Mycobacterium abscessus in a lung cavity","volume":"193","author":"Fennelly","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib0790","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fmicb.2020.00359","article-title":"Extreme drug tolerance of Mycobacterium abscessus \u201cPersisters.\u201d","volume":"11","author":"Yam","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib0795","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1128\/IAI.67.9.4700-4707.1999","article-title":"Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection","volume":"67","author":"Byrd","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.rmr.2023.10.010_bib0800","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1099\/mic.0.28625-0","article-title":"Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype","volume":"152","author":"Howard","year":"2006","journal-title":"Microbiology (Reading)"},{"key":"10.1016\/j.rmr.2023.10.010_bib0805","doi-asserted-by":"crossref","first-page":"e01206","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1460","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3346\/jkms.2008.23.1.49","article-title":"In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea","volume":"23","author":"Park","year":"2008","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.rmr.2023.10.010_bib1465","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0929-6646(08)60088-1","article-title":"Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002","volume":"107","author":"Huang","year":"2008","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.rmr.2023.10.010_bib1470","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/JCM.02260-12","article-title":"Comparative drug resistance of Mycobacterium abscessus and M. chelonae isolates from patients with and without cystic fibrosis in the United Kingdom","volume":"51","author":"Broda","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1475","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3343\/alm.2014.34.1.31","article-title":"The drug resistance profile of Mycobacterium abscessus group strains from Korea","volume":"34","author":"Lee","year":"2014","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1480","doi-asserted-by":"crossref","first-page":"419392","DOI":"10.1155\/2015\/419392","article-title":"Drug susceptibility testing of 31 antimicrobial agents on rapidly growing mycobacteria isolates from China","volume":"2015","author":"Pang","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.rmr.2023.10.010_bib0905","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cmi.2014.10.018","article-title":"Rapidly growing mycobacteria in Singapore, 2006\u20132011","volume":"21","author":"Tang","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2023.10.010_bib1455","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jinf.2015.12.007","article-title":"The antimicrobial susceptibility of non-tuberculous mycobacteria","volume":"72","author":"Cowman","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.rmr.2023.10.010_bib1485","doi-asserted-by":"crossref","first-page":"ofy022","DOI":"10.1093\/ofid\/ofy022","article-title":"Mycobacterium abscessus complex infections: a retrospective cohort study","volume":"5","author":"Sfeir","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib1490","doi-asserted-by":"crossref","first-page":"e4902941","DOI":"10.1155\/2018\/4902941","article-title":"In vitro susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum isolates to 30 antibiotics","volume":"2018","author":"Shen","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.rmr.2023.10.010_bib1495","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12890-018-0728-z","article-title":"Epidemiology of pulmonary disease due to nontuberculous mycobacteria in Southern China, 2013\u20132016","volume":"18","author":"Tan","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1500","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/dkaa520","article-title":"In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens","volume":"76","author":"Chew","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1505","doi-asserted-by":"crossref","first-page":"e01813","DOI":"10.1128\/JCM.01813-20","article-title":"Antimicrobial susceptibility and phylogenetic relations in a German cohort infected with Mycobacterium abscessus","volume":"58","author":"Wetzstein","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1100","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2147\/IDR.S252485","article-title":"Antimicrobial susceptibility of Mycobacterium abscessus complex clinical isolates from a Chinese Tertiary Hospital","volume":"13","author":"Guo","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.rmr.2023.10.010_bib1510","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijid.2020.06.007","article-title":"In vitro efficacy of combinations of eight antimicrobial agents against Mycobacteroides abscessus complex","volume":"97","author":"Shirata","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib0910","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1038\/s41598-021-91757-4","article-title":"Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan","volume":"11","author":"Kamada","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.rmr.2023.10.010_bib1515","series-title":"Performance standards for susceptibility testing of Mycobacteria, Nocardia spp., and other Aerobic Actinomycetes","year":"2018"},{"key":"10.1016\/j.rmr.2023.10.010_bib0810","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2023.10.010_bib0815","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1128\/AAC.46.10.3164-3167.2002","article-title":"Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous Mycobacteria","volume":"46","author":"Wallace","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0820","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib0825","doi-asserted-by":"crossref","first-page":"e00470","DOI":"10.1128\/AAC.00470-19","article-title":"In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0830","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/jac\/dkx212","article-title":"Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan","volume":"72","author":"Lee","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0835","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12879-017-2298-8","article-title":"Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan","volume":"17","author":"Hatakeyama","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib0840","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1128\/AAC.02448-14","article-title":"Lack of antimicrobial bactericidal activity in Mycobacterium abscessus","volume":"58","author":"Maurer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0845","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/AAC.03112-15","article-title":"Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0850","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41429-020-00392-0","article-title":"Comparison of two-drug combinations, amikacin\/tigecycline\/imipenem and amikacin\/tigecycline\/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay","volume":"74","author":"Portell-Buj","year":"2021","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.rmr.2023.10.010_bib0855","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0860","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/jac\/dkaa110","article-title":"Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo","volume":"75","author":"Pearce","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0865","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mimet.2018.03.020","article-title":"Evaluation of the intracellular activity of drugs against Mycobacterium abscessus using a THP-1 macrophage model","volume":"148","author":"Molina-Torres","year":"2018","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.rmr.2023.10.010_bib0870","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12941-020-00399-3","article-title":"Ex vivo infection of murine precision-cut lung tissue slices with Mycobacterium abscessus: a model to study antimycobacterial agents","volume":"19","author":"Molina-Torres","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.rmr.2023.10.010_bib0875","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/jit614","article-title":"In vivo evaluation of antibiotic activity against Mycobacterium abscessus","volume":"209","author":"Lerat","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib0880","doi-asserted-by":"crossref","first-page":"e01135","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0885","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/11317100-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of tigecycline","volume":"48","author":"Barbour","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmr.2023.10.010_bib0890","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/jac\/dku062","article-title":"Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections","volume":"69","author":"Wallace","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0895","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3389\/fmicb.2019.01977","article-title":"Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib0900","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rmed.2019.10.006","article-title":"Efficacy and safety of tigecycline for Mycobacterium abscessus disease","volume":"158","author":"Kwon","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib0915","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JCM.01612-13","article-title":"In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates","volume":"51","author":"Brown-Elliott","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib0920","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/jac\/dkw022","article-title":"Bactericidal and intracellular activity of \u03b2-lactams against Mycobacterium abscessus","volume":"71","author":"Lefebvre","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0925","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1128\/AAC.02282-15","article-title":"Amikacin pharmacokinetics\/pharmacodynamics in a novel hollow-fiber Mycobacterium abscessus disease model","volume":"60","author":"Ferro","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0930","doi-asserted-by":"crossref","first-page":"e02179","DOI":"10.1128\/AAC.02179-20","article-title":"Differential in vitro activities of individual drugs and bedaquiline-rifabutin combinations against actively multiplying and nutrient-starved Mycobacterium abscessus","volume":"65","author":"Lee","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0935","doi-asserted-by":"crossref","first-page":"e00236","DOI":"10.1128\/AAC.00236-20","article-title":"AR-12 exhibits direct and host-targeted antibacterial activity toward Mycobacterium abscessus","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0940","doi-asserted-by":"crossref","first-page":"e01782","DOI":"10.1128\/AAC.01782-17","article-title":"Mycobacterium abscessus smooth and rough morphotypes form antimicrobial-tolerant biofilm phenotypes but are killed by acetic acid","volume":"62","author":"Clary","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0945","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00134-007-0688-x","article-title":"Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients","volume":"33","author":"Boselli","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib0950","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0885066618754784","article-title":"Evaluation of epithelial lining fluid concentration of amikacin in critically ill patients with ventilator-associated pneumonia","volume":"35","author":"Najmeddin","year":"2020","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib0955","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jac\/48.2.325","article-title":"Serum pharmacokinetics and sputum penetration of amikacin 30\u00a0mg\/kg once daily and of ceftazidime 200\u00a0mg\/kg\/day as a continuous infusion in cystic fibrosis patients","volume":"48","author":"Byl","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib0960","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijantimicag.2013.07.014","article-title":"Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model","volume":"42","author":"Rey-Jurado","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.rmr.2023.10.010_bib0965","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12879-016-1689-6","article-title":"Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series","volume":"16","author":"Namkoong","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib0970","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.rmed.2010.12.012","article-title":"Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs","volume":"105","author":"Lyu","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib0975","doi-asserted-by":"crossref","first-page":"ofab215","DOI":"10.1093\/ofid\/ofab215","article-title":"Impact of susceptibility to injectable antibiotics on the treatment outcomes of Mycobacterium abscessus pulmonary disease","volume":"8","author":"Park","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib0980","first-page":"P4418","article-title":"Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease","volume":"42","author":"Ellender","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2023.10.010_bib0985","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40360-019-0302-1","article-title":"Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada","volume":"20","author":"Aznar","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.rmr.2023.10.010_bib0990","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Goble","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib0995","doi-asserted-by":"crossref","first-page":"R200","DOI":"10.1186\/cc8206","article-title":"Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia","volume":"13","author":"Luyt","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.rmr.2023.10.010_bib1000","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","article-title":"Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease","volume":"46","author":"Rubino","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.rmr.2023.10.010_bib1010","doi-asserted-by":"crossref","first-page":"e108703","DOI":"10.1371\/journal.pone.0108703","article-title":"Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection","volume":"9","author":"Rose","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2023.10.010_bib1015","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1128\/AAC.00986-07","article-title":"Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria","volume":"52","author":"Greendyke","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12879-017-2665-5","article-title":"The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases","volume":"17","author":"Yagi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib1025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/jamp.2010.0860","article-title":"Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure","volume":"24","author":"Luyt","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.rmr.2023.10.010_bib1030","doi-asserted-by":"crossref","first-page":"e00011","DOI":"10.1128\/AAC.00011-18","article-title":"Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease","volume":"62","author":"Jhun","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1035","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1040","doi-asserted-by":"crossref","first-page":"1801991","DOI":"10.1183\/13993003.01991-2018","article-title":"Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2023.10.010_bib1045","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.chest.2021.02.025","article-title":"Outcomes of inhaled amikacin-containing multidrug regimens for Mycobacterium abscessus pulmonary disease","volume":"160","author":"Kang","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2023.10.010_bib1050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cid\/ciw723","article-title":"Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense","volume":"64","author":"Park","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib1055","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/jac\/dkx284","article-title":"Effect of \u03b2-lactamase production and \u03b2-lactam instability on MIC testing results for Mycobacterium abscessus","volume":"72","author":"Rominski","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1060","doi-asserted-by":"crossref","first-page":"e00834","DOI":"10.1128\/JCM.00834-19","article-title":"Antimycobacterial susceptibility testing of nontuberculous mycobacteria","volume":"57","author":"Brown-Elliott","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1065","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/jac\/dku431","article-title":"Time\u2013kill kinetics of antibiotics active against rapidly growing mycobacteria","volume":"70","author":"Ferro","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1128\/AAC.23.2.323","article-title":"Comparative concentrations of cefoxitin in human lungs and sera","volume":"23","author":"Perea","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/clinids\/1.1.118","article-title":"Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency","volume":"1","author":"Humbert","year":"1979","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib1080","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/AAC.33.3.356","article-title":"Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination","volume":"33","author":"Ko","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1085","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1128\/AAC.02763-14","article-title":"Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group","volume":"58","author":"Czaja","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jac\/4.suppl_B.91","article-title":"Clinical safety and tolerance of cefoxitin sodium: an overview","volume":"4","author":"van Winzum","year":"1978","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1095","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1164\/rccm.200905-0704OC","article-title":"Antibiotic treatment of Mycobacterium abscessus lung disease","volume":"180","author":"Jeon","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1105","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/JCM.00298-16","article-title":"In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing Mycobacteria and Nocardia by use of Broth Microdilution and Etest","volume":"54","author":"Brown-Elliott","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1110","doi-asserted-by":"crossref","first-page":"e00623","DOI":"10.1128\/AAC.00623-18","article-title":"In vitro and intracellular activity of imipenem combined with rifabutin and avibactam against Mycobacterium abscessus","volume":"62","author":"Le Run","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1115","doi-asserted-by":"crossref","first-page":"e02548","DOI":"10.1128\/AAC.02548-19","article-title":"Synergistic interactions of indole-2-carboxamides and \u03b2-lactam antibiotics against Mycobacterium abscessus","volume":"64","author":"Raynaud","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1120","doi-asserted-by":"crossref","first-page":"e00114","DOI":"10.1128\/AAC.00114-20","article-title":"Efficacy of bedaquiline, alone or in combination with imipenem, against Mycobacterium abscessus in C3HeB\/FeJ Mice","volume":"64","author":"Le Moigne","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/18.Supplement_E.93","article-title":"The pharmacokinetics and tissue penetration of imipenem","volume":"18","author":"Wise","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jac\/20.5.725","article-title":"Imipenem kinetics in serum, lung tissue and pericardial fluid in patients undergoing thoracotomy","volume":"20","author":"Benoni","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1135","doi-asserted-by":"crossref","first-page":"e01411","DOI":"10.1128\/AAC.01411-17","article-title":"Intrapulmonary pharmacokinetics of relebactam, a novel \u03b2-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects","volume":"62","author":"Rizk","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1140","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jac\/dkn543","article-title":"Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5\u00a0h infusion","volume":"63","author":"Jaruratanasirikul","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1145","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1150","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/jac\/dku007","article-title":"Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus","volume":"69","author":"Maurer","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1164\/rccm.201003-0395OC","article-title":"Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus","volume":"183","author":"Koh","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1160","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.201111-2005OC","article-title":"Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance","volume":"186","author":"Choi","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1165","doi-asserted-by":"crossref","first-page":"e01879","DOI":"10.1128\/AAC.01879-19","article-title":"Dissecting erm(41)-mediated macrolide-inducible resistance in Mycobacterium abscessus","volume":"64","author":"Richard","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1170","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1128\/AAC.02615-15","article-title":"Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1175","doi-asserted-by":"crossref","first-page":"e02752","DOI":"10.1128\/AAC.02752-16","article-title":"Activity of LCB01-0371, a novel oxazolidinone, against Mycobacterium abscessus","volume":"61","author":"Kim","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1180","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1128\/AAC.00142-14","article-title":"In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic Zebrafish Test System","volume":"58","author":"Bernut","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1185","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/AAC.00459-15","article-title":"Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models","volume":"59","author":"Obreg\u00f3n-Henao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-199937050-00003","article-title":"Clinical pharmacokinetics of clarithromycin","volume":"37","author":"Rodvold","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmr.2023.10.010_bib1195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1440-1843.2007.01208.x","article-title":"Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid","volume":"13","author":"Kikuchi","year":"2008","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2023.10.010_bib1200","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/jac\/dkg355","article-title":"Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects","volume":"52","author":"Gotfried","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1205","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1128\/AAC.40.10.2375","article-title":"Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin","volume":"40","author":"Patel","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1210","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1128\/AAC.38.4.876","article-title":"Penetration of clarithromycin into lung tissues from patients undergoing lung resection","volume":"38","author":"Fish","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1215","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/jac\/dkn032","article-title":"Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin","volume":"61","author":"Lucchi","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1220","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/ciw724","article-title":"Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease","volume":"64","author":"Koh","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib1225","first-page":"e01146","article-title":"Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease","volume":"61","author":"Choi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1230","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jgar.2020.01.004","article-title":"Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: a propensity score analysis","volume":"22","author":"Kwon","year":"2020","journal-title":"J Global Antimicrob Resist"},{"key":"10.1016\/j.rmr.2023.10.010_bib1235","doi-asserted-by":"crossref","first-page":"ofab093","DOI":"10.1093\/ofid\/ofab093","article-title":"Tedizolid vs. linezolid for the treatment of nontuberculous mycobacteria infections in solid organ transplant recipients","volume":"8","author":"Poon","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib1240","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jac\/dkz511","article-title":"Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?","volume":"75","author":"Ruth","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1245","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/jac\/dkp267","article-title":"Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines","volume":"64","author":"Lemaire","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1250","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1255","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkg262","article-title":"Intrapulmonary penetration of linezolid","volume":"51","author":"Honeybourne","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1260","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/jac\/dks022","article-title":"Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia","volume":"67","author":"Boselli","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1265","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1270","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1183\/09031936.00169114","article-title":"The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease","volume":"45","author":"Winthrop","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2023.10.010_bib1275","doi-asserted-by":"crossref","first-page":"e00408","DOI":"10.1128\/aac.00408-22","article-title":"Linezolid exposure is associated with cytopenias in patients treated for multidrug-resistant tuberculosis","volume":"66","author":"Graciaa","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1280","series-title":"WHO consolidated guidelines on tuberculosis, module 4: treatment \u2013 drug-resistant tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.rmr.2023.10.010_bib1285","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1290","doi-asserted-by":"crossref","first-page":"O1124","DOI":"10.1111\/1469-0691.12780","article-title":"In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex","volume":"20","author":"Singh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.rmr.2023.10.010_bib1295","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome","volume":"159","author":"Kwak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2023.10.010_bib1300","doi-asserted-by":"crossref","first-page":"e02234","DOI":"10.1128\/AAC.02234-18","article-title":"In vitro synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the Mycobacterium abscessus complex","volume":"63","author":"Cheng","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1305","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria","volume":"74","author":"Ruth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1310","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.rmr.2023.10.010_bib1315","doi-asserted-by":"crossref","first-page":"e01881","DOI":"10.1128\/AAC.01881-19","article-title":"Assessment of clofazimine and TB47 combination activity against Mycobacterium abscessus using a bioluminescent approach","volume":"64","author":"Liu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1320","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1128\/AAC.00177-16","article-title":"Clofazimine contributes sustained antimicrobial activity after treatment cessation in a mouse model of tuberculosis chemotherapy","volume":"60","author":"Swanson","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1325","doi-asserted-by":"crossref","first-page":"e1002773","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs\u2019 distribution and emergence of resistance in patient's lung lesions: a mechanistic model and tool for regimen and dose optimization","volume":"16","author":"Strydom","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1330","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1335","doi-asserted-by":"crossref","first-page":"e47494","DOI":"10.1371\/journal.pone.0047494","article-title":"Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization","volume":"7","author":"Baik","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2023.10.010_bib1340","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2165\/00003088-198916020-00002","article-title":"Clinical pharmacokinetics of clofazimine","volume":"16","author":"Holdiness","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmr.2023.10.010_bib1345","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2023.10.010_bib1350","doi-asserted-by":"crossref","first-page":"e02052","DOI":"10.1128\/AAC.02052-16","article-title":"Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease","volume":"61","author":"Yang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1355","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3390\/jcm10194581","article-title":"In vitro activity and clinical outcomes of clofazimine for nontuberculous mycobacteria pulmonary disease","volume":"10","author":"Kim","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.rmr.2023.10.010_bib1360","doi-asserted-by":"crossref","first-page":"e0234621","DOI":"10.1128\/aac.02346-21","article-title":"In vitro bedaquiline and clofazimine susceptibility testing in Mycobacterium abscessus","volume":"66","author":"Schulthess","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1365","doi-asserted-by":"crossref","first-page":"e0239920","DOI":"10.1128\/AAC.02399-20","article-title":"Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant tuberculosis","volume":"65","author":"Ngwalero","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1370","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1038\/ncomms4369","article-title":"Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism","volume":"5","author":"Koul","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.rmr.2023.10.010_bib1375","doi-asserted-by":"crossref","first-page":"e0154521","DOI":"10.1128\/AAC.01545-21","article-title":"In vitro activity of bedaquiline and imipenem against actively growing, nutrient-starved, and intracellular Mycobacterium abscessus","volume":"65","author":"Martins","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1380","doi-asserted-by":"crossref","first-page":"1115530","DOI":"10.3389\/fcimb.2023.1115530","article-title":"Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB\/c mice models","volume":"13","author":"Zheng","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1385","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/antibiotics9020072","article-title":"Rifabutin suppresses inducible clarithromycin resistance in Mycobacterium abscessus by blocking induction of whiB7 and erm41","volume":"9","author":"Aziz","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.rmr.2023.10.010_bib1390","doi-asserted-by":"crossref","first-page":"e00283","DOI":"10.1128\/AAC.00283-18","article-title":"Rifabutin acts in synergy and is bactericidal with frontline Mycobacterium abscessus antibiotics clarithromycin and tigecycline, suggesting a potent treatment combination","volume":"62","author":"Pryjma","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1395","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/22.Supplement_1.S15","article-title":"The clinical pharmacokinetics of rifabutin","volume":"22","author":"Blaschke","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib1400","doi-asserted-by":"crossref","first-page":"e00363","DOI":"10.1128\/AAC.00363-20","article-title":"Rifabutin is bactericidal against intracellular and extracellular forms of Mycobacterium abscessus","volume":"64","author":"Johansen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1405","doi-asserted-by":"crossref","first-page":"e01943","DOI":"10.1128\/AAC.01943-19","article-title":"Rifabutin is active against Mycobacterium abscessus in mice","volume":"64","author":"Dick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1410","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-017-0601-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of oxazolidinones","volume":"57","author":"Roger","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rmr.2023.10.010_bib1415","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3389\/fmicb.2018.02095","article-title":"Tedizolid activity against clinical Mycobacterium abscessus complex isolates\u00a0\u2013\u00a0an in vitro characterization study","volume":"9","author":"Tang","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1420","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/AAC.05354-11","article-title":"Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers","volume":"56","author":"Housman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1425","doi-asserted-by":"crossref","first-page":"e00356","DOI":"10.1128\/AAC.00356-20","article-title":"Safety and tolerability of more than six days of tedizolid treatment","volume":"64","author":"Mensa Vendrell","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.rmr.2023.10.010_bib1430","doi-asserted-by":"crossref","first-page":"ofac028","DOI":"10.1093\/ofid\/ofac028","article-title":"Real-world use of tedizolid phosphate for 28 days or more: a case series describing tolerability and clinical success","volume":"9","author":"Morrisette","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib1435","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/JCM.02950-14","article-title":"Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs","volume":"53","author":"Brown-Elliott","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1440","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fmicb.2014.00178","article-title":"Antivirulence activity of azithromycin in Pseudomonas aeruginosa","volume":"5","author":"Imperi","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.rmr.2023.10.010_bib1445","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI46095","article-title":"Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection","volume":"121","author":"Renna","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rmr.2023.10.010_bib1450","doi-asserted-by":"crossref","first-page":"S736","DOI":"10.1093\/ofid\/ofaa439.1649","article-title":"1468. Culture conversion and mortality in patients with Mycobacterium abscessus (MAB) lung disease: a systematic literature review","volume":"7","author":"Winthrop","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.rmr.2023.10.010_bib0760","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","article-title":"Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis","volume":"152","author":"Diel","year":"2017","journal-title":"Chest"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842523002711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842523002711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:25:39Z","timestamp":1760106339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842523002711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0761842523002711"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2023.10.010","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyse pharmacologique du traitement des pneumopathies \u00e0 Mycobacterium abscessus","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2023.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}